Health Discovery Corporation Announces Issuance of New U.S. Patent Covering SVM-Based Image Analysis Including Digital Mammography.

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB:HDVY) announced that this week the U.S. Patent and Trademark Office issued the Company its latest SVM-related patent, Patent No. 6,996,549, covering the use of multiple Support Vector Machines ("SVM") for processing different types of data that can be extracted from digitized images such as those found in digital mammography.

Last fall, the New England Journal of Medicine reported a landmark breast cancer screening trial showing that digital mammography detected more cancers -- up to 28% more -- than screen film mammography in certain groups of women. Millennium Research Group, a medical device analysis firm, has predicted significant growth in the market for digital breast imaging, from about $200M in 2004 to more than $450M by 2009. A key to successful market growth will be implementation of computer-aided detection software, such as that covered by HDC's newest patent. HDC now owns seventeen (17) issued U.S. and foreign patents covering uses of SVM pattern recognition technology.

Most currently available software for digital mammography rely on artificial neural networks. Neural network classification methods, which have been in use for image classification for a decade or more, suffer from a number of drawbacks that negatively impact their reliability. Published research has shown that SVMs are superior to neural networks in characterizing microcalcification clusters in digitized mammograms.

"This latest issuance adds considerable strength to our entire SVM intellectual property portfolio," said Stephen D. Barnhill, M.D., HDC's Chairman & CEO. "We now hold pioneer patents covering a range of SVM applications from pre-processing all the way through to instantaneous diagnosis and monitoring of diseases over the Internet. This presents the opportunity for physicians around the world to gain point 'n' click access to the most advanced computer assisted diagnostic ("CAD") tools for analysis of blood, tissues and all digital images such as X-rays, MRI's, PET scans and others."

Other applications of HDC's newly issued patent include analysis of microscopic images of samples, such as tissue and blood, from a patient. Examples of such applications for blood samples include circulating tumor and endothelial cell analyses, which are gaining recognition as predictive of outcome in certain cancers like breast cancer and have significant value in determining the direction and monitoring efficacy of treatment. Examples of tissue samples include microscopic images for surgical specimens, PAP smears and biopsies for determining diagnosis and progression of cancer. The ability to automatically analyze every image using CAD software and produce a summary result, as provided by HDC's patented method, greatly increases the reliability of the analysis as well as the time required to complete it. HDC's additional claims covering in vivo analysis methods and their applications are pending before the U.S. Patent Office.

HDC's issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple SVMs and for multiple data sets, and providing SVM analysis services over the Internet. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVM's including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

Savannah-based Health Discovery Corporation (OTCBB:HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker and pathway discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's pattern recognition technology also holds significant application potential in other sizable commercial markets such as diagnostics, Internet search and spam, homeland security, financial futures and other areas where analysis of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.